It's a darn shame that Ricky's post hasn't come through, but - ever helpful - let me fill the void and post on his behalf. Ricky was trying to tell us that:
1. He told us so, but he can't really remember when or how.
2. He sold all of his SGEN at the all-time high of $55.99, but forgot to mention it at the time.
3. This is all the Bakers' fault, though he can't say precisely how.
4. Ten is ten.
5. For emphasis, he told us so, but he can't quite remember when or how.
fjmardejetko: Yep, still in CLDX. Also CGEN and, of course, SGEN.
jazz harper: Hard to know what to say. Hope you don't reach Stage III so you won't need Adcetris for frontline HL, but if you do cross that unhappy threshold, I bet that you'll find a way to get into the trial. Or, perhaps, the trial will already have led to authorized use.
Nearly the entire biotech space has been hit during the last week in one of those cyclical swings. SGEN's investment rationale has not changed a bit. Consequently, though generally not a trader, I just bought back a small batch that I sold in the $50s.
Yep, that apparently was the main factor. That caused most biotechs to plunge, taking the market with it. I've added the Nasdaq Biotech Index (NBI) to my watch list. I should have done that a long time ago.
Again, short-term, options-related manipulation. The bad guys will close it at or very close to $50. Then, within days or at most a week or so, it will recover. Happens all the time. It's frustrating, for sure. But, in the long run, it's meaningless, imo.
amplicon, completely agreed on all points. I don't/won't watch Cramer on a regular basis, because when I do, I can feel my brain cells dying, but I do try to catch his segments about SGEN and anything else I may have a large stake in. While introducing these interviews, he reads whatever is placed in front of him, usually inarticulately, and he comprehends not a shred of what he's reading. Frankly, some of his questions last night to Siegall were borderline offensive when it comes to patients and their health and fate.
As for Yahoo, just be glad you don't own any of its stock (I'm assuming this). It's one screwed-up company that can't get itself unscrewed. Regarding these boards, Yahoo keeps fiddling with them, making them worse each time. Most recently, for God knows what reason - probably just inadvertently, Yahoo took away the box in which you could jump to other stock message boards.
You're making a mistake if you pay any attention to Maui. Something's not right with him. The subject of a secondary didn't come up last night or in the recent past.
CEO Clay Siegall did a terrific job last night, explaining very clearly the near-term and long-term prospects for Seattle Genetics. The entire six-minute segment was incredibly upbeat. Cramer is a complete idiot - this was one of the worst, most primitive interviews I've ever seen - but he likes SGEN, and that certainly helps us.
Yahoo (Our Motto: Every Update Makes Things Worse) won't let us post links anymore, but you can find the interview on Youtube if you Google this: CYqqwnkUuQ0
The Cantor opinion you reference was issued on Aug. 1, 2013. What you saw today was a roundup of previous - and in many cases old - recommendations by Cantor. From Seeking Alpha on Aug. 7, 2013: "On Thursday August 1st, Analysts at Cantor Fitzgerald issued a target price of $24 a share with a "sell" recommendation as they see the potential downside of the stock could drop 40.77% from its July 31st close."
Since that opinion by Cantor, the stock has advanced from $40.52 on July 31 to around $51, a gain of more than 25 percent.
I couldn't care less about short-term ups and downs, but I will say that the trading in SGEN today (and over the last few days) has been particularly strange. It feels like some entity is accumulating, imo.
Well, let's put it this way: A lot of my net worth, probably too much, is concentrated in SGEN, CGEN and CLDX.
I didn’t hear any news, but also never was heard a discouraging word.
The prime takeaway: Many catalysts are coming during the rest of this year in the form of trial results involving Adcetris and other ADCs produced by SGEN and its partners. Look for these results during ASCO and ASH and at other, less predictable times.
“It’s going to be a very strong year for Seattle Genetics,” Siegel told the investors, repeatedly using the terms “exciting results” and “we’re very excited.”
The replay is available now through the link on SGEN's investor page.
Wow. Tough crowd to please. High volume, low volume, whatever. Stock is up 42 percent since Jan. 6. I'll settle for that at this point.
Actually, you're on the right track. This guy moves around about as frequently as a goat shepard. Based on his skill analyzing SGEN's science, I'm sure I'd be thrilled having him work on developing new drugs for my company.
NEW YORK, Jan. 7, 2014 (GLOBE NEWSWIRE) -- Cortice Biosciences, a biotechnology company developing novel agents for the treatment of oncologic and neurologic indications, announced today the appointment of George Farmer, Ph.D. as Chief Executive Officer.
Dr. Farmer brings more than 20 years of industry, financial, and academic experience to Cortice. Most recently, he served as Vice President, Corporate Development at Synta Pharmaceuticals, a company developing novel treatments for cancer. As a Senior Biotechnology Analyst with Canaccord Genuity, Wachovia Securities, and Fortis Bank, Dr. Farmer covered a wide range of companies developing and commercializing drugs for many therapeutic indications. He also served as a Senior Scientist at DuPont Pharmaceuticals Company and completed post-doctoral fellowships at Memorial Sloan Kettering Cancer Center and University of California San Francisco investigating molecular mechanisms of cancer progression. Dr. Farmer received his Ph.D. in Biological Sciences from Columbia University and a B.A. from Dartmouth College….
Needham analyst, Chad Messer says the company's platform and ADCETRIS could turn SGEN into "the next large cap drug company."
Messer wrote in a research note, "Seattle Genetics is developing antibody drug conjugates (ADCs) to fight cancer. The company's technology platform has been validated by a plethora of clinical data, numerous partnerships, and one successful drug approval and launch. Sales of flagship lymphoma drug, Adcetris, have been modest so far at $145 million in 2013. However, we believe Adcetris has much greater potential and forecast $2 billion in worldwide sales by 2020. More importantly, we believe that Seattle Genetic's leadership with ADC technology make it one a small number of mid-cap biotech companies with the ability to generate long term growth sufficient to become a sustainable large cap drug company."
Yeah, some shorts are moving back in. Que sera sera. Here's a recent tweet from one genius: Beat Bartlome @3xKona 2m $SGEN Took a short position here. Admittedly risky in this strength, so not for the weak of heart.
With 1 million shares traded within the first 30 minutes and the stock easily breaking $50 for the first time, I think it is safe to say that a short squeeze has been underway this morning.
scr2002, as an SGEN investor since around 2007, I certainly understand your impatience insofar as I've also fallen victim to it from time to time. But, at the same time, I know this: Every thing that Siegall and his team have promised would happen over the years has, indeed, happened. Consequently, my considerable holding of SGEN shares has increased in value by more than 500 percent.
You might want to keep in mind that, in many ways, this is a company still deep within the research and development phase. Thus, research costs and losses may widen for a bit longer. But, if Siegall says he intends to grow this into a company with a market cap two, three or even four times its current size, I'm willing, based on his success thus far, to give him the benefit of the doubt.
Also, note that the Baker brothers remain firm holders and now the Vanguards of the world are taking positions in SGEN not at the prices that you and I did, but at these current, much higher prices. I don't know about you, but I'm pretty sure that the Bakers and the other big institutions are smarter than I am about these things. So, if they're happy and hopeful, I am, too.